X

Trial Profile

A Phase 2 Study of IRL-201104 for Allergan Sensitivity

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 03 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IRL 201104 (Primary)
Indications Hypersensitivity
Focus Therapeutic Use
Sponsors Revolo Biotherapeutics

Most Recent Events

28 Feb 2023 According to Revolo media release, data from this study is expected in Q2 of 2023.
15 Apr 2021 According to a Revolo Biotherapeutics media release, company has entered into a Master Service Agreement with a Contract Development & Manufacturing Organization (CDMO), CordenPharma, for the production of 1104, to support upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease,that are expected to initiate before the end of 2021.
12 Mar 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com